Koers Canntab Therapeutics Limited Deutsche Boerse AG
Aandelen
TBF1
CA1377991023
Farmaceutische producten
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,0005 EUR | -.--% | -.--% | -.--% |
Omzet 2021 | - | Omzet 2022 | 0,29 0,27 | Marktkapitalisatie | 11,48 mln. 10,57 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -4 mln. -3,68 mln. | Nettowinst (verlies) 2022 | -3 mln. -2,76 mln. | EV/omzet 2021 | - |
Nettoschuld 2021 | 75,05K 69,11K | Nettoschuld 2022 | 1,15 mln. 1,06 mln. | EV/omzet 2022 | 43.043.762 x |
K/w-verhouding 2021 |
-7,9
x | K/w-verhouding 2022 |
-3,02
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 86,26% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 63 | 20-04-16 | |
President | 56 | 20-04-16 | |
Chief Tech/Sci/R&D Officer | - | 15-05-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
President | 56 | 20-04-16 | |
Barry Polisuk
BRD | Director/Board Member | 61 | 11-04-18 |
Vitor Fonseca
BRD | Director/Board Member | 71 | 11-04-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+44,36% | 6,34 mld. | |
-13,52% | 4,61 mld. | |
+10,85% | 3,39 mld. | |
-6,52% | 3,29 mld. | |
+51,14% | 2,02 mld. | |
-5,22% | 1,73 mld. | |
+1,29% | 1,67 mld. | |
+57,69% | 1,63 mld. | |
-9,67% | 1,59 mld. |
- Beurs
- Aandelen
- Koers PILL
- Koers TBF1